Abstract: A system and method for the detection of saliva biomarkers in bodily fluids is described. In particular, the system is suitable for detecting biomarkers of lung cancer in a subject. The system includes an electrochemical sensor chip having at least one well, wherein the at least one well contains a working electrode coated with a conducting polymer functionalized with at least one capture probe, and at least one labeled detector probe. When the at least one labeled detector probe is mixed with a sample of the subject containing a biomarker of lung cancer and added to the at least one well, an electric current is applied to the sample, such that when at least some of the biomarker binds to the capture probe, a measurable change in electric current in the sample is created that is indicative of lung cancer.

Abstract: A semiconductor quantum dot is provided with a non-metallic substrate, and has a particle size ranged from 0.3 to 100 nm. A method of carrying out a chemical reaction or a photoluminescence reaction by using the semiconductor quantum dot is also provided. A redox reaction of a target sample is carried out, an active substance is generated, or an electron-hole pair is produced from the semiconductor quantum dot by providing the semiconductor quantum dot with a predetermined energy. Photons are released by the combination of the electron-hole pair so as to perform the photoluminescence reaction.

Abstract: A molecular probe includes a detector molecule specific to a target molecule, and at least one label linked covalently or non-covalently to the detector molecule. The label includes a catalyst for generating electrons and/or mediators from a solution. The catalyst includes a nanomaterial, an enzyme, a metal, and/or a metal complex. The mediators can accumulate in the solution for a period of time. The detector molecule and the target molecule interact with each other by a protein based or nucleotide sequence based interaction. The mediators participate in a chemical reaction that generates a signal that may be a change in optical, electromagnetic, thermodynamic or mechanical properties. Generation efficiency of the mediators is enhanced by providing an energy to the solution. The molecular probe may be used with a molecular detection assay performed on a surface. A method for assaying the target molecule using the molecular probe is also provided.

Abstract: A pharmaceutical composition includes a plurality of metal nanoparticles and at least one therapeutic agent. Each of the metal nanoparticles includes a core and a stabilizing agent coated on a surface of the core. The at least one therapeutic agent is attached to the stabilizing agent of the metal nanoparticles. Each of the therapeutic agent is an amphiphilic compound and has at least one hydrophobic chain interacting with the stabilizing agent. The pharmaceutical composition may further include a polymer shell encapsulating the metal nanoparticles and the therapeutic agent for enabling controlled release of the therapeutic agent. The pharmaceutical compositions are bifunctional and may be used for diagnosing and treating cancer. Methods for using the pharmaceutical compositions in conjunction with radiation therapy to diagnose and treat cancer are also provided.

Abstract: A semiconductor quantum dot is provided with a non-metallic substrate, and has a particle size ranged from 0.3 to 100 nm. A method of carrying out a chemical reaction or a photoluminescence reaction by using the semiconductor quantum dot is also provided. A redox reaction of a target sample is carried out, an active substance is generated, or an electron-hole pair is produced from the semiconductor quantum dot by providing the semiconductor quantum dot with a predetermined energy. Photons are released by the combination of the electron-hole pair so as to perform the photoluminescence reaction.

Abstract: A pharmaceutical composition includes a plurality of metal nanoparticles and at least one therapeutic agent. Each of the metal nanoparticles includes a core and a stabilizing agent coated on a surface of the core. The at least one therapeutic agent is attached to the stabilizing agent of the metal nanoparticles. Each of the therapeutic agent is an amphiphilic compound and has at least one hydrophobic chain interacting with the stabilizing agent. The pharmaceutical composition may further include a polymer shell encapsulating the metal nanoparticles and the therapeutic agent for enabling controlled release of the therapeutic agent. The pharmaceutical compositions are bifunctional and may be used for diagnosing and treating cancer. Methods for using the pharmaceutical compositions in conjunction with radiation therapy to diagnose and treat cancer are also provided.

Abstract: A molecular probe includes a detector molecule specific to a target molecule, and at least one label linked covalently or non-covalently to the detector molecule. The label includes a catalyst for generating electrons and/or mediators from a solution. The catalyst includes a nanomaterial, an enzyme, a metal, and/or a metal complex. The mediators can accumulate in the solution for a period of time. The detector molecule and the target molecule interact with each other by a protein based or nucleotide sequence based interaction. The mediators participate in a chemical reaction that generates a signal that may be a change in optical, electromagnetic, thermodynamic or mechanical properties. Generation efficiency of the mediators is enhanced by providing an energy to the solution. The molecular probe may be used with a molecular detection assay performed on a surface. A method for assaying the target molecule using the molecular probe is also provided.

Abstract: A reaction system comprises at least one additive and at least one reaction base-plane for augmenting chemical reaction, photoelectrochemical reaction, photochemical reaction or electrochemical reaction. The reaction system further comprises at least one reaction substrate carried out to the chemical reaction, the photoelectrochemical reaction, the photochemical reaction or the electrochemical reaction with the at least one additive and the at least one reaction base-plane. The at least one additive is a kind of reaction enhancer added in the reaction system to improve, augment or accumulate the effeteness of at least one reaction result.

Abstract: A system and method for the detection of saliva biomarkers in bodily fluids is described. In particular, the system is suitable for detecting biomarkers of lung cancer in a subject. The system includes an electrochemical sensor chip having at least one well, wherein the at least one well contains a working electrode coated with a conducting polymer functionalized with at least one capture probe, and at least one labeled detector probe. When the at least one labeled detector probe is mixed with a sample of the subject containing a biomarker of lung cancer and added to the at least one well, an electric current is applied to the sample, such that when at least some of the biomarker binds to the capture probe, a measurable change in electric current in the sample is created that is indicative of lung cancer.

Abstract: A method for determining a treatment response of cells is provided with steps of providing a un-treated first sample and a treated second sample; applying an electric signal to the first sample and the second sample; obtaining a first motion parameter of the first sample and a second motion parameter of the second sample in the electric signal, respectively; and comparing the first motion parameter and the second motion parameter to determine whether there is a difference. The difference represents that the treatment response exists.

Abstract: A non-metallic semiconductor quantum dot is provided with a non-metallic substrate, and has a particle size ranged from 0.3 to 100 nm. A method of carrying out a chemical reaction or a photoluminescence reaction by using the non-metallic semiconductor quantum dot is also provided. A redox reaction of a target sample is carried out, an active substance is generated, or an electron-hole pair is produced from the non-metallic semiconductor quantum dot by providing the non-metallic semiconductor quantum dot with a predetermined energy. Photons are released by the combination of the electron-hole pair so as to perform the photoluminescence reaction.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: The present invention is related to a composition of PI3K inhibitor, comprising: 0.01˜10 mg of PI3K inhibitor; 10˜500 mg of poly(lactic-co-glycolic acid) (PLGA) which is encapsulated onto the surface of the PI3K inhibitor and the surface is non-modified by a modifier; and the composition has a size of 10˜1000 nm. Thereby, an excellent effect on suppressing the growth of tumor cells will be achieved by the encapsulation of PI3K inhibitor into PLGA nanomaterials without any modifier on its surface, the optimization of a ratio of PI3K inhibitor to PLGA, and the accordingly slow release of the composition.

Abstract: A nucleic acid cleavage kit is used to cleave a target nucleic acid. The nucleic acid cleavage kit includes a carrier, an oligonucleotide, and a nucleic acid cleavage agent. The oligonucleotide recognizes at least partial sequence of the target nucleic acid. Then, the nucleic acid cleavage agent cleaves the target nucleic acid. A nucleic acid cleavage detection apparatus including the nucleic acid cleaving kit and a gene therapy by administering the nucleic acid cleavage kit are also disclosed.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: A nucleic acid cleavage kit is used to cleave a target nucleic acid. The nucleic acid cleavage kit includes a carrier, an oligonucleotide, and a nucleic acid cleavage agent. The oligonucleotide recognizes at least partial sequence of the target nucleic acid. Then, the nucleic acid cleavage agent cleaves the target nucleic acid. A nucleic acid cleavage detection apparatus including the nucleic acid cleaving kit and a gene therapy by administering the nucleic acid cleavage kit are also disclosed.